Efficacy of Long-term Flecainide Therapy in Patients with Paroxysmal Atrial Fibrillation: Analysis Based on Time of Onset

Journal of Arrhythmia

Volumn 22, Issue 1, 2006, Pages 37-43

  Komatsu, Takashi ^a   Satou, Yoshihiro ^a   Tachibana, Hideaki ^a   Nakamura, Motoyuki ^a   Okumura, Ken ^b   Nakamura, Shin ^c   Suzuki, Osamu ^c   Horiuchi, Daisuke ^c   Yomogida, Kunihiko ^c  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Iwate Prefectural Iwai Hospital   (Japan)

Author keywords

Antiarrhythmic drug therapy; Circadian variation; Flecainide; Paroxysmal atrial fibrillation

Indexed keywords

EID: 76749139335     PISSN: 18804276     EISSN: 18832148     Source Type: Journal    
DOI: 10.4020/jhrs.22.37     Document Type: Article

References (32)

1. Yamashita T, Murakawa Y, Sezaki K, Inoue M, Hayami N, Shuzui Y, et al: Circadian variation of paroxysmal atrial fibrillation. Circulation 1997; 96: 1537-1541
2. Komatsu T, Yomogida K, Nakamura S, Saitou E, Kobayashi T, Okumura K, et al: Efficacy of disopyr-amide in the termination and long-term prevention of paroxysmal atrial fibrillation estimated by the time of onset. Shinzo 2001; 33: 29-35 (in Japanese)
3. Komatsu T, Nakamura S, Kimura M, Owada S, Saitou E, Okumura K, et al: Efficacy of cibenzoline in the termination and long-term prevention of paroxysmal atrial fibrillation: Analysis based on the time of onset. J Cardiol 2001; 37: 75-82 (in Japanese with English abstract)
4. Komatsu T, Nakamura S, Kimura M, Owada S, Tomita H, Okumura K, et al: Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: Analysis based on the time of onset. J Cardiol 2001; 38: 211-217 (in Japanese with English abstract)
5. WHO (1978): Arterial hypertension. WHO Technical Report Series. 628, 1978
6. Task force of the working group on arrhythmias of the European Society of Cardiology: The Sicilian Gambit; A new approach to the classification of antiarrhythmic drugs based on their action on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851
7. Kodama I, Toyama J, Takanaka C, Yamada K: Block of activated and inactivated sodium channels by class-I antiarrhythmic drug studied using maximum upstroke velocity (V max) of action potential in guinea-pig cardiac muscles. J Mol Cell Cardiol 1987; 19: 367-377
8. Katoh T, Iinuma H, Inoue H, Ohe T, Ogawa S, Kasanuki H, et al: Multicenter prospective nonrandomized study of long-term antiarrhythmic drug therapy in patients with tachyarrhythmias: Japanese Antiarrhythmics Long-Term Study-2 (JALT-2 Study). Jpn Circ J 2001; 65: 275-278
9. Singh BN and Houswirth O: Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 1974; 86: 367-378
10. Watanabe H, Watanabe I, Nakai T, Oshikawa N, Kunimoto S, Masaki R, et al: Frequency-dependent electrophysiological effects of flecainide, nifekalant, and d,l-sotalol on the human atrium. Jpn Circ J 2001; 65: 1-6
11. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV: Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987; 59: 1337-1341
12. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al: Prevention of symptomatic recurrence of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557-1570
13. Pietersen AH, Hellemann H, for the Danish-Norwegian Flecainide Multicenter Study Group: Usefulness of flecainide for prevention of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1991; 67: 713-717
14. Lau CP, Leung WH, Wong CK: A randomized double-blind crossover study comparing the efficacy and toler-ability of flecainide and qunidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992; 124: 645-650
15. Pritchett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and atrial fibrillation. Dose-response studies. J Am Coll Cardiol 1991; 17: 297-303
16. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P: Flecainide acetate in the prevention of paroxysmal atrial fibrillation. A nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70: 44A-50A
17. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P: Prospective comparison of flecainide versus qunidine for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1996; 77: 53A-59A
18. Aliot E, Denjoy I, for the Flecainide AF French Study Group: Comparison of the safety and efficacy of flecainide versus propafenone in hospital outpatients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77: 66A-71A
19. Mary-Rabine L, Kulbertus HE: Clinical efficacy of flecainide acetate in atrial fibrillation. Cardiology 1990; 77: 443-449
20. Komatsu T, Nakamura S, Saitou E, Kobayashi T, Kumagai K, Okumura K, et al: Long-term preventive effects of pilsicainide, flecainide and bepridil on the recurrence of atrial fibrillation refractory to Ia and Ib antiarrhythmic drugs. Sinzo 2000; 32: 699-705 (in Japanese)
21. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666
22. Wit AL, Rosen MR: Afterdepolarizations and triggered activity: Distinction from automaticity as an arrhythmo-genic mechanism. In Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (eds): The Heart and Cardiovascular System. Scientific Foundations. New York, NY: Raven Press, Ltd., 1992, pp 2113-2163
23. Matsuda JJ, Lee H, Shibata EF: Enhancement of rabbit cardiac sodium channels by beta-adrenergic stimulation. Circ Res 1992; 70: 199-207
24. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ: Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220-222
25. Bigger JT Jr., Rolnitzky LM, Steinman RC, Fleiss JL: Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. J Am Coll Cardiol 1994; 23: 733-740
26. Clair WK, Wilkonson WE, McCarthy EA, Page RL, Pritchett EL: Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraven-tricular tachycardia in untreated patients. Circulation 1993; 87: 1114-1122
27. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS: Amiodarone for refractory atrial fibrillation. Am J Cardiol 1996; 57: 124-127
28. Suttorp MJ, Kingma JH, Koomen EM, van't Hof A, Tijssen JG, Lie KI: Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal ventricular function. Am J Cardiol 1993; 71: 710-713
29. Komatsu T, Nakamura S, Saitou E, Kobayashi T, Kumagai K, Okumura K: Long-term efficacy of antiar-rhythmic drugs in the prevention of paroxysmal atrial fibrillation; Significance of suffering period. Jpn J Electrocardiology 2000; 20: 27-32 (in Japanese)
30. Saito H, Sasabe N, Osaka M, Ino T, Atarashi H, Katoh T, et al: Autonomic nervous activity preceding paroxysmal tachycardic arrhythmias. Jpn J Electrocardiology 1993; 13: 181-188 (in Japanese)
31. Tomoda Y, Uemura S, Fujimoto S, Fujishima T: Autonomic nervous activity in patients with paroxysmal atrial fibrillation. J Cardiol 1998; 31: 11-17 (in Japanese with English abstract)
32. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL: Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227